Company & Sponsor Intelligence
Biohaven Pharmaceuticals, Inc.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting1
Completed1
Countries1
Therapeutic footprint
alsocdother_neurology
Indexed studies
NCT03701399Troriluzole in Adult Participants With Spinocerebellar Ataxia
other_neurology · United StatesPHASE3
other_neurology · United StatesPHASE3
NCT04708834Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
ocd · United StatesPHASE3
ocd · United StatesPHASE3
NCT03520517Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
als · United StatesPHASE1
als · United StatesPHASE1
Intelligence layer updated: 2026-10-20 06:14:04.499488+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →